malignant pheochromocytoma malignant paraganglioma
Conditions
Interventions
Sunitinib
Sponsors
Department of Urology, Kyoto University, Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Diagnosed with malignant pheochromcytoma or paraganglioma 2) ECOG performance status; 0-2 3) Unresectable 4) Age; 20-755 5) neutrophil below 1,500/uL Hb below 8.5g/dL PLT below 100,000/uL AST(GOT) above 65IU/L ALT(GPT) above 210IU/L Ejection Fraction below 50% Serum Cre above 1.5mg/dL 6) Informed consent; Agreement by a document
Exclusion criteria
Exclusion criteria: 1) Brain metastasis 2) Existence of other malignancy before registration for less than 5 years. 3) Treatment history with other tyrosine kinase inhibitors or anti-angiogenic drugs. 4) Severe liver dysfunction; Child-Pugh classification C 5) History of previous hypersensitivity for an ingredient of sutent. 6) The women who has possibility of or hopes for the pregnancy.Breast-feeding mother. The men who hopes for the pregnancy of a partner. 7) Difficulty in participating to an study due to psychiatric disorders. 8) The case that Chief Researcher or doctor judge as unsuitable for enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Adverse event/Side effect Disease control rate | — |
Secondary
| Measure | Time frame |
|---|---|
| Time to treatment failure Response Rate | — |
Countries
Japan
Contacts
Public ContactYamasaki Toshinari
Kyoto University, Graduate School of Medicine Department of Urology
Outcome results
None listed